Drugs

Anti-Interleukin-2 Receptor Antibodies in Transplantation: What is the Basis for Choice?
pp. 1737-1741(5)
Authors: Teun van Gelder; Michiel Warlé; Rik G. ter Meulen

Augmentation Therapy for ₁-Antitrypsin Deficiency
pp. 1743-1756(14)
Authors: Georges S. Juvelekian; James K. Stoller

Heart Rate Lowering by Specific and Selective If Current Inhibition with Ivabradine: A New Therapeutic Perspective in Cardiovascular Disease
pp. 1757-1765(9)
Authors: Dario DiFrancesco; John A. Camm

Managing Immunogenic Responses to Infliximab: Treatment Implications for Patients with Crohn’s Disease
pp. 1767-1777(11)
Authors: Peter D. Han; Russell D. Cohen

Repeat Prescribing: Scale, Problems and Quality Management in Ambulatory Care Patients
pp. 1779-1800(22)
Authors: Peter A.G.M. De Smet; Maaike Dautzenberg

Drug-Gene Interactions between Genetic Polymorphisms and Antihypertensive Therapy
pp. 1801-1816(16)
Authors: Hedi Schelleman; Bruno H. Ch. Stricker; Anthonius de Boer; Abraham A. Kroon; Monique W.M. Verschuren; Cornelia M. van Duijn; Bruce M. Psaty; Olaf H. Klungel

Pharmacological Therapy for Acromegaly: A Critical Review
pp. 1817-1838(22)
Authors: Alex F. Muller; Aart Jan van der Lely

Paclitaxel: As Adjuvant or Neoadjuvant Therapy in Early Breast Cancer
pp. 1839-1847(9)
Authors: Dene Simpson; Greg L. Plosker

Paclitaxel in Early Breast Cancer: A Viewpoint by Aman U. Buzdar
pp. 1848-1849(2)
Author: Aman U. Buzdar

Paclitaxel in Early Breast Cancer: A Viewpoint by David A. Cameron
pp. 1848-1849(2)
Author: David A. Cameron